Omnipaque 350 755 mg (Iohexol SOLUTION) 755 MG

Omnipaque 350 is a radiocontrast agent used for diagnostic imaging procedures. This solution contains iohexol 755 mg per 100 mL, available in various pack sizes. It helps enhance visibility during imaging.

Strength

755 MG

Pack Size

50/100/150/200/500 ML

Manufacturer / TM Owner

GE HEALTHCARE CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Omnipaque 350 is primarily used as a contrast medium for diagnostic imaging. It is often administered to improve the clarity of structures within the body during procedures like CT scans or angiograms. This helps healthcare professionals obtain detailed images for better diagnosis. What is Omnipaque 350 used for? It is commonly used in medical imaging to enhance the visibility of internal body structures.

Side Effects

Omnipaque 350 may cause temporary discomfort or a warm sensation during administration. Some individuals might experience mild side effects such as nausea or headache. These effects are generally short-lived and resolve quickly.

Precautions & Warnings

Omnipaque 350 should be used with caution in individuals with known allergies to contrast agents. It is important to inform healthcare professionals about any existing medical conditions or allergies before administration. Proper handling and storage are essential to maintain the integrity of the solution.

Avoid Interactions

Omnipaque 350 may interact with certain medications or substances. It is advisable to consult with a healthcare professional about potential interactions, especially if taking other medications. Alcohol and certain drugs might affect the body's response to the contrast agent.

Frequently Asked Questions

Omnipaque 350 is used as a contrast medium to enhance the visibility of internal body structures during diagnostic imaging procedures.

Omnipaque 350 is typically administered orally or intravenously, depending on the specific imaging procedure.

Common side effects may include nausea, headache, or a warm sensation during administration, which are usually temporary.

Omnipaque 350 should be used with caution in individuals with known allergies to contrast agents. Consult a healthcare professional for personalized advice.

Omnipaque 350 is available in various pack sizes, including 50 mL, 100 mL, 150 mL, 200 mL, and 500 mL.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.